103 related articles for article (PubMed ID: 8422285)
1. Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide.
Anderson E; Ferguson JE; Morten H; Shalet SM; Robinson EL; Howell A
Eur J Cancer; 1993; 29A(2):209-17. PubMed ID: 8422285
[TBL] [Abstract][Full Text] [Related]
2. Serum bioactive lactogenic hormone levels in women with familial breast cancer and their relatives.
Anderson E; Morten H; Wang DY; Burns P; Birch J; Howell A
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1719-25. PubMed ID: 2632255
[TBL] [Abstract][Full Text] [Related]
3. Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer.
Manni A; Boucher AE; Demers LM; Harvey HA; Lipton A; Simmonds MA; Bartholomew M
Breast Cancer Res Treat; 1989 Dec; 14(3):289-98. PubMed ID: 2575406
[TBL] [Abstract][Full Text] [Related]
4. Serum prolactin and growth hormone determined by radioimmunoassay and a two-site immunoradiometric assay: comparison with the Nb2 cell bioassay.
Rose DP; Berke B; Cohen LA
Horm Metab Res; 1988 Jan; 20(1):49-53. PubMed ID: 3371857
[TBL] [Abstract][Full Text] [Related]
5. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
6. Bioactive forms of serum lactogens: effects of treatment of prolactinoma patients with bromocriptine.
Rennie PS; Prior JC; Bruchovsky N; Gout PW
Clin Endocrinol (Oxf); 1985 Jan; 22(1):65-73. PubMed ID: 3978829
[TBL] [Abstract][Full Text] [Related]
7. A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines.
Lissoni P; Bucovec R; Malugani F; Ardizzoia A; Villa S; Gardani GS; Vaghi M; Tancini G
Anticancer Res; 2002; 22(2B):1131-4. PubMed ID: 12168912
[TBL] [Abstract][Full Text] [Related]
8. Invasive mixed growth hormone/prolactin secreting pituitary tumour: complete shrinking by octreotide and bromocriptine, and lack of tumour growth relapse 20 months after octreotide withdrawal.
Sadoul JL; Thyss A; Freychet P
Acta Endocrinol (Copenh); 1992 Feb; 126(2):179-83. PubMed ID: 1543025
[TBL] [Abstract][Full Text] [Related]
9. Acromegaly and hyperprolactinemia in a patient with polyostotic fibrous dysplasia: dynamic endocrine studies and treatment with the somatostatin analogue octreotide.
Garcia MB; Koppeschaar HP; Lips CJ; Thijssen JH; Krenning EP
J Endocrinol Invest; 1994 Jan; 17(1):59-65. PubMed ID: 7911814
[TBL] [Abstract][Full Text] [Related]
10. A prospective multicenter octreotide dose response study in the treatment of acromegaly.
Ezzat S; Redelmeier DA; Gnehm M; Harris AG
J Endocrinol Invest; 1995 May; 18(5):364-9. PubMed ID: 7594225
[TBL] [Abstract][Full Text] [Related]
11. Prolactin levels and hormonal profile in postmenopausal patients with advanced breast cancer during endocrine treatments.
Pannuti F; Martoni A; Farabegoli G; Piana E
Chemioterapia; 1985 Apr; 4(2):127-34. PubMed ID: 3159487
[TBL] [Abstract][Full Text] [Related]
12. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly.
Fløgstad AK; Halse J; Grass P; Abisch E; Djøseland O; Kutz K; Bodd E; Jervell J
J Clin Endocrinol Metab; 1994 Aug; 79(2):461-5. PubMed ID: 8045964
[TBL] [Abstract][Full Text] [Related]
13. Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy.
Hyer SL; Sharp PS; Brooks RA; Burrin JM; Kohner EM
Acta Endocrinol (Copenh); 1989 Feb; 120(2):187-94. PubMed ID: 2916380
[TBL] [Abstract][Full Text] [Related]
14. Circulating levels of growth hormone, insulin-like growth factor-I and prolactin in normal, growth retarded and anencephalic human fetuses.
Arosio M; Cortelazzi D; Persani L; Palmieri E; Casati G; Baggiani AM; Gambino G; Beck-Peccoz P
J Endocrinol Invest; 1995 May; 18(5):346-53. PubMed ID: 7594222
[TBL] [Abstract][Full Text] [Related]
15. The effect of the somatostatin analog SMS 201-995 on normal growth hormone secretion in the rat. A comparison with the effect of bromocriptine on normal prolactin secretion.
Lamberts SW; Verleun T; Zuiderwijk JM; Oosterom R
Acta Endocrinol (Copenh); 1987 Jun; 115(2):196-202. PubMed ID: 2885995
[TBL] [Abstract][Full Text] [Related]
16. CV 205-502 in acromegaly.
Chiodini PG; Attanasio R; Cozzi R; Dallabonzana D; Oppizzi G; Orlandi P; Strada S; Liuzzi A
Acta Endocrinol (Copenh); 1993 May; 128(5):389-93. PubMed ID: 8100375
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
Suda K; Inoshita N; Iguchi G; Fukuoka H; Takahashi M; Nishizawa H; Yamamoto M; Yamada S; Takahashi Y
Endocr J; 2013; 60(4):507-15. PubMed ID: 23291436
[TBL] [Abstract][Full Text] [Related]
18. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly.
Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ; Liuzzi A
Acta Endocrinol (Copenh); 1983 Aug; 103(4):446-50. PubMed ID: 6310918
[TBL] [Abstract][Full Text] [Related]
19. Acromegalic gigantism with low serum level of growth hormone and elevated serum insulin-like growth factor-I.
Miyazaki R; Yoshida T; Sakane N; Yasuda T; Umekawa T; Kondo M; Shimatsu A; Hizuka N; Sano T
Intern Med; 1995 Mar; 34(3):183-7. PubMed ID: 7787324
[TBL] [Abstract][Full Text] [Related]
20. Recurrent acromegaly resulting from ectopic growth hormone gene expression by a metastatic pancreatic tumor.
Ezzat S; Ezrin C; Yamashita S; Melmed S
Cancer; 1993 Jan; 71(1):66-70. PubMed ID: 8416728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
